Current Impact and Application of Abuse-Deterrent Opioid Formulations in Clinical Practice

被引:1
|
作者
Lee, Ya-Han [1 ]
Brown, Daniel L. [2 ]
Chen, Hsiang-Yin [1 ,3 ]
机构
[1] Taipei Med Univ, Sch Pharm, Dept Clin Pharm, 250 Wu Hsin St, Taipei, Taiwan
[2] Calif Hlth Sci Univ, Coll Pharm, Clovis, CA USA
[3] Taipei Med Univ, Wan Fang Hosp, Dept Pharm, Taipei, Taiwan
关键词
Opioid abuse; abuse-deterrent formulations; ADF; post-marketing; FDA guidance; cost impact; abuse liking; physician attitude; generic abuse-deterrent formulation; clinical application; TAMPER-RESISTANT FORMULATIONS; EXTENDED-RELEASE HYDROCODONE; UNITED-STATES; CHRONIC PAIN; DOUBLE-BLIND; POSTOPERATIVE PAIN; SUBSTANCE-ABUSE; RISK-EVALUATION; NONMEDICAL USE; SINGLE-ENTITY;
D O I
暂无
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Abuse-deterrent formulations (ADFs) represent one novel strategy for curbing the potential of opioid abuse. Objective: We aim to compare and contrast the characteristics and applications of current abuse-deterrent opioid products in clinical practice. Methods: Literature searches were conducted in databases (Pubmed Medline, International Pharmaceutical Abstracts, Google Scholar) and official reports. Relevant data were screened and organized into: 1) epidemiology of opioid abuse, 2) mitigation strategies for reducing opioid abuse, 3) development of ADFs, and 4) clinical experience with these formulations. Results: Increasing trends of opioid abuse and misuse have been reported globally. There are 5 types of abuse-deterrent opioid products: physical chemical barrier, combined agonist/antagonist, sequestered aversive agent, prodrug, and novel delivery system. The advantages and disadvantages of the 5 options are discussed in this review. A total of 9 products with abuse-deterrent labels have been approved by the Food and Drug Administration (FDA). The rates of abuse, diversion, and overdose deaths of these new products are also discussed. A framework for collecting in-time data on the efficacy, benefit and risk ratio, and cost-effectiveness of these new products is suggested to facilitate their optimal use. Limitations: The present review did not utilize systematic review standards or meta-analytic techniques, given the large heterogeneity of data and outcomes reviewed. Conclusions: ADFs provide an option for inhibiting the abuse or misuse of oral opioid products by hindering extraction of the active ingredient, preventing alternative routes of administration, or causing aversion. Their relatively high costs, uncertain insurance policies, and limited data on pharmacoeconomics warrant collaborative monitoring and assessment by government agencies, pharmaceutical manufacturers, and data analysis services to define their therapeutic role in the future.
引用
收藏
页码:E1003 / E1023
页数:21
相关论文
共 50 条
  • [41] Emerging Trends in Abuse-Deterrent Formulations: Technological Insights and Regulatory Considerations
    Rana, Dhwani
    Salave, Sagar
    Benival, Derajram
    CURRENT DRUG DELIVERY, 2022, 19 (08) : 846 - 859
  • [42] The Effect of an Abuse-Deterrent Opioid Formulation (OxyContin) on Opioid Abuse-Related Outcomes in the Postmarketing Setting
    Coplan, P. M.
    Chilcoat, H. D.
    Butler, S. F.
    Sellers, E. M.
    Kadakia, A.
    Harikrishnan, V.
    Haddox, J. D.
    Dart, R. C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 100 (03) : 275 - 286
  • [43] Abuse-deterrent formulations: Part 2: commercial products and proprietary technologies
    Mastropietro, David J.
    Omidian, Hossein
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (03) : 305 - 323
  • [44] Abuse-deterrent extended-release oxycodone and risk of opioid-related harm
    Paljarvi, Tapio
    Strang, John
    Quinn, Patrick D.
    Luciano, Sierra
    Fazel, Seena
    ADDICTION, 2021, 116 (09) : 2409 - 2415
  • [45] A tale of 2 ADFs: differences in the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs
    Cicero, Theodore J.
    Ellis, Matthew S.
    Kasper, Zachary A.
    PAIN, 2016, 157 (06) : 1232 - 1238
  • [46] Abuse-Deterrent Formulations in Constraining the Abuse Potential of Pre-scription Medicines: A Myth or Truth
    Phaugat, Parmita
    Nishal, Suchitra
    Dhiman, Rakhi
    CURRENT DRUG DELIVERY, 2022, 19 (04) : 466 - 478
  • [47] Abuse-deterrent formulations: transitioning the pharmaceutical market to improve public health and safety
    Simon, Kyle
    Worthy, Stacey L.
    Barnes, Michael C.
    Tarbell, Benjamin
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2015, 6 (02) : 67 - 79
  • [48] Variation in Abuse-Deterrent Formulation Opioid Prescribing in California, Florida, and Kentucky in 2018
    Brown, John R.
    Oh, GYeon
    Wang, Yanning
    Slavova, Svetla
    Delcher, Chris
    Dasgupta, Nabarun
    Freeman, Patricia R.
    JOURNAL OF RURAL HEALTH, 2021, 37 (01) : 23 - 28
  • [49] Design of Abuse-Deterrent Formulations Using Various Types of Thermal Deformed Starch (TDS)
    Sohn, Jeong Sun
    Choi, Jin-Seok
    JOURNAL OF PHARMACEUTICAL INNOVATION, 2023, 18 (04) : 1638 - 1654
  • [50] Design of Abuse-Deterrent Formulations Using Various Types of Thermal Deformed Starch (TDS)
    Jeong Sun Sohn
    Jin-Seok Choi
    Journal of Pharmaceutical Innovation, 2023, 18 : 1638 - 1654